Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Top-down infliximab versus step-up therapy in pediatric Crohn's disease
NL-OMON39629Recruiting
- Sponsor
- Erasmus MC
- Start
- Jan 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of infliximab, azathioprine and prednisolone in Crohn's disease and inflammatory bowel disease (IBD) (2 arms), sponsored by Erasmus MC. Primary endpoint: Steroid-free remission at 52 weeks. Started Jan 2013; status: recruiting.
02
Drugs
infliximabazathioprineprednisolone
03
Conditions
Crohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON39629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39629.